PPGLs show marked skeletal tropism, with 75.7% of patients developing bone metastases, primarily in the spine, after surgical resection.
FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Syncromune®, Inc., a clinical-stage biopharmaceutical ...
In November 2025, Rana McKay, MD initiated a phase 2 study of the combination of cabozantinib + nivolumab in subjects with advanced castration-resistant prostate cancer (CRPC). DelveInsight's Bone ...
Erratum: TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study The following represents disclosure information ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback